Paper · 25119024
Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function.
Viale A and 29 others. Nature, 2014. Cited by 1,097 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Papers, record 25119024. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/25119024
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Publication types
- Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- PubMed
Topics21
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carcinoma, Pancreatic Ductal | Major topic |
| Mitochondria | Major topic |
| Pancreatic Neoplasms | Major topic |
| Proto-Oncogene Proteins p21(ras) | Major topic |
| Animals | |
| Autophagy | |
| Cell Respiration | |
| Cell Survival | |
| Disease Models, Animal | |
| Female | |
| Gene Expression Regulation, Neoplastic | |
| Genes, p53 | |
| Glycolysis | |
| Lysosomes | |
| Mice | |
| Mutation | |
| Neoplasm Recurrence, Local | |
| Neoplastic Stem Cells | |
| Oxidative Phosphorylation | |
| Recurrence | |
| Signal Transduction |
Source PubMed
Grants10
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| P30CA16672 | NCI NIH HHS | United States | P01CA016672 | PubMed and NIH | NIH RePORTER |
| P30 CA016672 | NCI NIH HHS | United States | P01CA016672 | PubMed and NIH | NIH RePORTER |
| CA16672 | NCI NIH HHS | United States | P01CA016672 | PubMed and NIH | NIH RePORTER |
| P01 CA117969 | NCI NIH HHS | United States | P01CA117969 | PubMed and NIH | NIH RePORTER |
| P01CA117969 | NCI NIH HHS | United States | P01CA117969 | PubMed and NIH | NIH RePORTER |
| P01CA120964 | NCI NIH HHS | United States | P01CA120964 | PubMed and NIH | NIH RePORTER |
| P50 CA127003 | NCI NIH HHS | United States | P50CA127003 | PubMed and NIH | NIH RePORTER |
| P01 CA120964 | NCI NIH HHS | United States | P01CA120964 | PubMed and NIH | NIH RePORTER |
| CA016672 | NCI NIH HHS | United States | P01CA016672 | PubMed and NIH | NIH RePORTER |
| P30CA016672 | NIH | NIH RePORTER |
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections2
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Erratum in | 41,951,747 | Author Correction: Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. | https://conductscience.org/library/papers/41951747 | PubMed |
| Comment in | 25,155,173 | Targeted therapy: Targeting mitochondria in pancreatic cancer. | https://conductscience.org/library/papers/25155173 | PubMed |
References29
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 15,994,921 | K-ras codon-specific mutations produce distinctive metabolic phenotypes in NIH3T3 mice [corrected] fibroblasts. | Cancer Res | 2005 | https://conductscience.org/library/papers/15994921 | PubMed |
| 2 | 20,818,844 | Inhibition of mutated, activated BRAF in metastatic melanoma. | N Engl J Med | 2010 | https://conductscience.org/library/papers/20818844 | PubMed |
| 3 | 19,876,027 | Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice. | Nat Protoc | 2009 | https://conductscience.org/library/papers/19876027 | PubMed |
| 4 | 19,652,654 | Imatinib and beyond--exploring the full potential of targeted therapy for CML. | Nat Rev Clin Oncol | 2009 | https://conductscience.org/library/papers/19652654 | PubMed |
| 5 | 21,847,114 | Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth. | Mol Syst Biol | 2011 | https://conductscience.org/library/papers/21847114 | PubMed |
| 6 | 11,870,241 | Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. | N Engl J Med | 2002 | https://conductscience.org/library/papers/11870241 | PubMed |
| 7 | 23,321,785 | P2Y1R-initiated, IP3R-dependent stimulation of astrocyte mitochondrial metabolism reduces and partially reverses ischemic neuronal damage in mouse. | J Cereb Blood Flow Metab | 2013 | https://conductscience.org/library/papers/23321785 | PubMed |
| 8 | 21,695,188 | ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma. | PLoS One | 2011 | https://conductscience.org/library/papers/21695188 | PubMed |
| 9 | 18,568,040 | Ras oncogenes: split personalities. | Nat Rev Mol Cell Biol | 2008 | https://conductscience.org/library/papers/18568040 | PubMed |
| 10 | 19,339,967 | Autophagy regulates lipid metabolism. | Nature | 2009 | https://conductscience.org/library/papers/19339967 | PubMed |
1 to 10 of 29
See all 29 referencesCited by840
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1,097 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,967,940 | Molecular and immune heterogeneity across limited-stage and extensive-stage small cell lung cancer. | Exp Mol Med | 2026 | https://conductscience.org/library/papers/42967940 | PubMed |
| 42,936,416 | NDUFS1 promotes malignant breast cancer behaviors through enhancement of mitochondrial respiration and PROX1/c-Myc signaling. | iScience | 2026 | https://conductscience.org/library/papers/42936416 | PubMed |
| 42,926,286 | Integrated Functional and Metabolomic Profiling of Melanoma Cells Treated with Redox-Active Compounds. | Methods Mol Biol | 2027 | https://conductscience.org/library/papers/42926286 | PubMed |
| 42,923,094 | Epigenetic adaptations and vulnerabilities in ovarian cancer drug-tolerant persister cells. | NAR Cancer | 2026 | https://conductscience.org/library/papers/42923094 | PubMed |
| 42,857,319 | Research progress of pancreatic cancer based on ferroptosis-cuproptosis interaction (Review). | Oncol Lett | 2026 | https://conductscience.org/library/papers/42857319 | PubMed |
| 42,818,236 | ALDH1B1 promotes mitochondrial γ-butyrobetaine biosynthesis and fatty acid oxidation in colorectal cancer. | bioRxiv | 2026 | https://conductscience.org/library/papers/42818236 | PubMed |
| 42,698,921 | Spatiotemporal control of mitoribosome-mediated metabolic reprogramming in cancer: implications for heterogeneity and therapeutic targeting. | Front Cell Dev Biol | 2026 | https://conductscience.org/library/papers/42698921 | PubMed |
| 42,669,625 | DLST Succinylation-Mediated Mitochondrial Metabolic Remodeling and Cuproptosis Resistance Promote Malignant Progression of Lung Adenocarcinoma. | Adv Sci (Weinh) | 2026 | https://conductscience.org/library/papers/42669625 | PubMed |
| 42,666,728 | Autophagy inhibition in pancreatic cancer: hope or hype? | Autophagy Rep | 2026 | https://conductscience.org/library/papers/42666728 | PubMed |
| 42,653,862 | A Bioactivated Lepidium latifolium Formulation Disrupts Mitochondrial Bioenergetics and Metabolic Adaptation in KRAS-Mutant Cancer Cells. | Molecules | 2026 | https://conductscience.org/library/papers/42653862 | PubMed |
1 to 10 of 840
See all 840 cited byGenes16
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ABCD1 | 215 | PubTator's text mining | https://conductscience.org/library/genes/215 | NCBI Gene |
| AKT1 | 207 | PubTator's text mining | https://conductscience.org/library/genes/207 | NCBI Gene |
| ANXA5 | 308 | PubTator's text mining | https://conductscience.org/library/genes/308 | NCBI Gene |
| EIF2AK3 | 9,451 | PubTator's text mining | https://conductscience.org/library/genes/9451 | NCBI Gene |
| HSP90AA1 | 3,320 | PubTator's text mining | https://conductscience.org/library/genes/3320 | NCBI Gene |
| KRAS | 3,845 | PubTator's text mining | https://conductscience.org/library/genes/3845 | NCBI Gene |
| MAP2K7 | 5,609 | PubTator's text mining | https://conductscience.org/library/genes/5609 | NCBI Gene |
| MAPK1 | 5,594 | PubTator's text mining | https://conductscience.org/library/genes/5594 | NCBI Gene |
| PIK3CD | 5,293 | PubTator's text mining | https://conductscience.org/library/genes/5293 | NCBI Gene |
| POTEF | 728,378 | PubTator's text mining | https://conductscience.org/library/genes/728378 | NCBI Gene |
1 to 10 of 16
See all 16 genesDrugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data1
The data bank entries PubMed's record names. Trial numbers are under Trials.
| Data bank | Accession |
|---|---|
| GEO | GSE58307 |
Source GEO
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/25119024
GET https://conductscience.org/api/papers/v1/25119024/authors?page=2